Mission

LSC’s overarching goal is to enable member companies to work together to remove roadblocks and to find new ways to accelerate discovery and development of new therapies for all cancer patients.

Specific tactics include the following:

Consortium History

An LSC Task Force was commissioned during the fourth annual meeting of the CEO Roundtable on Cancer in June 2003. The Task Force was asked to explore the creation of a forum to enhance and speed cancer drug discovery and early drug development, thereby bringing improved therapies to cancer patients faster. LSC was charged with exploring the formation of a consortium that would unite the research-intensive pharmaceutical and biotech industry with each other, as well as with the National Cancer Institute, Centers for Disease Control and Prevention, U.S. Food and Drug Administration, and academic centers of excellence.

Impact/Accomplishment

Project Data Sphere, LLC, an independent, not-for-profit initiative of LSC, operates the Project Data Sphere® platform  (www.ProjectDataSphere.org), which provides one place where the research community can broadly share, integrate, and analyze historical, patient-level, cancer Phase III comparator-arm data with the goal of advancing future research to improve the lives of cancer patients and their families around the world.

The START clauses represent a toolkit that provides standardized legal language for key agreement elements common to most clinical trial agreements. By starting the negotiation process with commonly agreed upon language, the START clauses can simplify and accelerate the contracting process. Although developed with cancer clinical trials in mind, the START clauses are applicable to all types of clinical research.

Links/Social Media Feed

Points of Contact

Gregory A. Curt
Co-Chair, Life Sciences Consortium
email: Gregory.Curt@astrazeneca.com

Mace Rothenberg
Co-Chair, Life Sciences Consortium
email: Mace.Rothenberg@pfizer.com

Sponsors & Partners